Wolfe Research Upgrades Vertex Pharmaceuticals to Outperform, Announces $548 Price Target

Benzinga · 3d ago
Wolfe Research analyst Andy Chen upgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Peer Perform to Outperform and announces $548 price target.